Editor - Neuro-Oncology Advances

@EditorNeuro

Dr. Gelareh Zadeh - Editor-in-Chief of the Neuro-Oncology Advances Journal http://academic.oup.com/noa @gelarehzadeh

Joined February 2022

363Following

2KFollowers

Pinned

Editor - Neuro-Oncology Advances@EditorNeuro · Feb 27, 2022

We welcome working with you on manuscripts in any area of #braintumor #CancerResearch #cancercare #spinetumors #metastases #pediatricbraintumor #molecularpathology #Neurosurgery #neuroscience of #braincancer & more [email protected] academic.oup.com/noa

EditorNeuro's tweet card. Neuro-Oncology Advances is an Open Access journal covering basic, applied, and clinical investigations in all areas as they relate to cancer and the central nervous system. NOA welcomes direct...

113

Pinned

Editor - Neuro-Oncology Advances@EditorNeuro · 23 h

What is the utility of arterial spin labeling perfusion MRI (#ASLMRI) for accurately differentiating between #RadiationNecrosis and tumor in #BrainMetastases treated with #StereotacticRadiosurgery? Read the article in our latest issue: bit.ly/4lEf83A

EditorNeuro's tweet image. What is the utility of arterial spin labeling perfusion MRI (#ASLMRI) for accurately differentiating between #RadiationNecrosis and tumor in #BrainMetastases treated with #StereotacticRadiosurgery?

Read the article in our latest issue: bit.ly/4lEf83A

200

Editor - Neuro-Oncology Advances@EditorNeuro · Jul 23

At #NeuroOncology Advances, we are proud to be an open access journal. @OxUniPress aims to achieve the widest possible dissemination of high-quality research, upholding the highest standards of publication ethics & integrity. Learn more about #OpenAccess: academic.oup.com/pages/open-res…

EditorNeuro's tweet image. At #NeuroOncology Advances, we are proud to be an open access journal. @OxUniPress aims to achieve the widest possible dissemination of high-quality research, upholding the highest standards of publication ethics &amp; integrity.

Learn more about #OpenAccess: academic.oup.com/pages/open-res…

151

Editor - Neuro-Oncology Advances@EditorNeuro · Jul 21

Findings: - Distant progression is associated with poor prognosis - Unmethylated MGMT, multicentric disease, and NF1 alteration predict distant progression - NF1 alteration is a prognostic factor and may serve as a predictive factor for targeted treat bit.ly/4kwjybt

EditorNeuro's tweet image. Findings:
- Distant progression is associated with poor prognosis
- Unmethylated MGMT, multicentric disease, and NF1 alteration predict distant progression
- NF1 alteration is a prognostic factor and may serve as a predictive factor for targeted treat

bit.ly/4kwjybt

311

Editor - Neuro-Oncology Advances@EditorNeuro · Jul 18

Read “PNOC009: Convection-enhanced delivery of liposomal irinotecan in patients with newly diagnosed diffuse intrinsic pontine #glioma” in our latest issue: bit.ly/40KXRNO

EditorNeuro's tweet image. Read “PNOC009: Convection-enhanced delivery of liposomal irinotecan in patients with newly diagnosed diffuse intrinsic pontine #glioma” in our latest issue: bit.ly/40KXRNO

247

Editor - Neuro-Oncology Advances@EditorNeuro · Jul 16

Our new article “Refinement of primary central nervous system #lymphoma #prognostication and response assessment using 3-dimensional MRI” is now available. Read the #LaySummary or full article here: bit.ly/46E59qp

EditorNeuro's tweet image. Our new article “Refinement of primary central nervous system #lymphoma #prognostication and response assessment using 3-dimensional MRI” is now available.

Read the #LaySummary or full article here: bit.ly/46E59qp

328

Editor - Neuro-Oncology Advances Retweeted

SNO@NeuroOnc · Jul 14

There's still time to register for the next broadcast of the SNO Storm: Pediatric Tumor Board Series. The broadcast entitled Infant High-Grade Glioma: Not All High-Grade Gliomas are Born Equal will occur live on Tuesday, July 15, 2025, 1:00-2:30 pm ET bit.ly/3GJMRJK

800

Editor - Neuro-Oncology Advances@EditorNeuro · Jul 14

Recent research found that #temozolomide rechallenge is a common, safe, and effective second-line option for patients with MGMT-methylated, #IDHwildtype #GBM following first-line lomustine/temozolomide therapy. Read the full article in our latest issue: bit.ly/4497BUq

EditorNeuro's tweet image. Recent research found that #temozolomide rechallenge is a common, safe, and effective second-line option for patients with MGMT-methylated, #IDHwildtype #GBM following first-line lomustine/temozolomide therapy.

Read the full article in our latest issue: bit.ly/4497BUq

562

Editor - Neuro-Oncology Advances@EditorNeuro · Jul 11

In case you missed it, our new Clarivate #ImpactFactor and 5 year impact factor is now out! To read more about our metrics at #NeuroOncology Advances, click below. bit.ly/3GyhT7n

EditorNeuro's tweet image. In case you missed it, our new Clarivate #ImpactFactor and 5 year impact factor is now out!

To read more about our metrics at #NeuroOncology Advances, click below.

bit.ly/3GyhT7n

272

Editor - Neuro-Oncology Advances@EditorNeuro · Jul 9

How might certain genetic changes influence how long #IDHmutant #astrocytomas patients live? Read the #LaySummary or full article here: bit.ly/3IccSSt

EditorNeuro's tweet image. How might certain genetic changes influence how long #IDHmutant #astrocytomas patients live?

Read the #LaySummary or full article here: bit.ly/3IccSSt

3.0K

Editor - Neuro-Oncology Advances@EditorNeuro · Jul 7

We have new #articles coming out every week - here are our latest ones published in #NeuroOncology Advances. To access these, click here and scroll to the bottom of the page: bit.ly/3un7GEJ

EditorNeuro's tweet image. We have new #articles coming out every week - here are our latest ones published in #NeuroOncology Advances.

To access these, click here and scroll to the bottom of the page: bit.ly/3un7GEJ

217

Editor - Neuro-Oncology Advances@EditorNeuro · Jul 4

We are very pleased to announce that the new #ImpactFactor for #NeuroOncology Advances is now 4.1 (up from 3.7 the previous year)!

EditorNeuro's tweet image. We are very pleased to announce that the new #ImpactFactor for #NeuroOncology Advances is now 4.1 (up from 3.7 the previous year)!

1.0K

Editor - Neuro-Oncology Advances@EditorNeuro · Jul 2

The initial response to induction #chemotherapy is an important prognostic factor in primary central nervous system lymphoma (#PCNSL) - this was the finding of some recent research. Read the full article here: bit.ly/3ToBGct

EditorNeuro's tweet image. The initial response to induction #chemotherapy is an important prognostic factor in primary central nervous system lymphoma (#PCNSL) - this was the finding of some recent research.

Read the full article here: bit.ly/3ToBGct

381

Editor - Neuro-Oncology Advances@EditorNeuro · Jun 30

Solitary fibrous tumors/#hemangiopericytoma are rare central #CNS exhibiting high recurrence rates and the ability to metastasize. This study evaluated #SFT prognosis and survival outcomes, focusing on the 2021 WHO classification. #LaySummary & article: bit.ly/4lnwJwp

EditorNeuro's tweet image. Solitary fibrous tumors/#hemangiopericytoma are rare central #CNS exhibiting high recurrence rates and the ability to metastasize. This study evaluated #SFT prognosis and survival outcomes, focusing on the 2021 WHO classification.

#LaySummary &amp; article: bit.ly/4lnwJwp

599

Editor - Neuro-Oncology Advances@EditorNeuro · Jun 27

Looking for in-depth #metrics on your published #articles? #NeuroOncology Advances provides a range of third-party metrics, giving you insight into the performance, reach, and impact at title level or for individual #research outputs. Find out more: bit.ly/4ei9PEg

EditorNeuro's tweet image. Looking for in-depth #metrics on your published #articles?

#NeuroOncology Advances provides a range of third-party metrics, giving you insight into the performance, reach, and impact at title level or for individual #research outputs.

Find out more: bit.ly/4ei9PEg

179

Editor - Neuro-Oncology Advances@EditorNeuro · Jun 25

Although small subsets of #Glioblastoma patients survive longer than 3 years, there is little evidence regarding the prognostic factors of #GBM. Therefore, this study conducted a thorough characterization of GBM in the United States. Read full article: bit.ly/44glbnQ

EditorNeuro's tweet image. Although small subsets of #Glioblastoma patients survive longer than 3 years, there is little evidence regarding the prognostic factors of #GBM. Therefore, this study conducted a thorough characterization of GBM in the United States.

Read full article: bit.ly/44glbnQ

476

Editor - Neuro-Oncology Advances@EditorNeuro · Jun 23

Does the #resection location have an impact on #depressive symptoms following #glioma surgery? Read the lay summary or full article in our latest issue: bit.ly/3G2sSFW

EditorNeuro's tweet image. Does the #resection location have an impact on #depressive symptoms following #glioma surgery?

Read the lay summary or full article in our latest issue: bit.ly/3G2sSFW

273

Editor - Neuro-Oncology Advances@EditorNeuro · Jun 20

We are proud to have a very easy and straightforward article submission process, with ease of use and quick submission to decision. Learn more here: bit.ly/3UvsGUl #NeuroOncologyAdvances #NeuroOncology #oncology #CancerResearch

EditorNeuro's tweet image. We are proud to have a very easy and straightforward article submission process, with ease of use and quick submission to decision.

Learn more here: bit.ly/3UvsGUl

#NeuroOncologyAdvances #NeuroOncology #oncology #CancerResearch

363

Editor - Neuro-Oncology Advances@EditorNeuro · Jun 18

This new study in NOA is the first study to describe the framework and patient profile of a #multidisciplinary #AYA #NeuroOncology clinic in a quaternary #CancerCenter in #Canada. Read about it now: bit.ly/4mSmOjY

568

Editor - Neuro-Oncology Advances@EditorNeuro · Jun 16

Integrating early #PalliativeCare in #glioblastoma management is feasible - this was the conclusion of a recently conducted study. Read the full clinical investigation in our latest issue: bit.ly/4mWBtuw

EditorNeuro's tweet image. Integrating early #PalliativeCare in #glioblastoma management is feasible - this was the conclusion of a recently conducted study.

Read the full clinical investigation in our latest issue: bit.ly/4mWBtuw

526

Editor - Neuro-Oncology Advances@EditorNeuro · Jun 13

Given the poor predictive value of #GeneticBiomarkers in #glioblastoma, this study conducted a prospective #ClinicalTrial to investigate the novel approach of cultivated patient-derived tumor cells (PDCs) for ex vivo drug screening. Read more: bit.ly/3SBOE6a

EditorNeuro's tweet image. Given the poor predictive value of #GeneticBiomarkers in #glioblastoma, this study conducted a prospective #ClinicalTrial to investigate the novel approach of cultivated patient-derived tumor cells (PDCs) for ex vivo drug screening.

Read more: bit.ly/3SBOE6a

247